GLP-1R agonists and SGLT2 inhibitors were found to significantly reduce the risk of major cardiovascular events in diabetes mellitus and are recommended as first-line therapies for the management of type 2 diabetes in patients at increased cardiovascular risk. This evidence concerns the gene SLC5A2 and diabetes mellitus.